Drug Trial Radar · NCT02801097
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
Last checked: Nov 19, 2026Latest source record: May 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
28
Actual
Start
Aug 30, 2016
Primary completion
Nov 22, 2018
Study completion Dec 9, 2019
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan. RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability of RRx-001 to restore the expression of aberrantly silenced genes, thus re-establishing pathway functions. However, resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular modulation, leading to improved penetration of standard chemotherapy.
Conditions
- Malignant Solid Tumor
- Metastatic Cancer
- Advanced Cancer
Interventions
RRx-001Drug
IrinotecanDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number, frequency and type of adverse eventsTime frame: 14 Weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of California, Davis
Sacramento, California
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.